



Scheme IV<sup>a</sup>

<sup>a</sup> (i)  $\text{ClCH}_2\text{OCH}_3$ ,  $(i\text{-Pr})_2\text{NEt}$ ,  $\text{CH}_2\text{Cl}_2$ , room temperature, 4 h, 98%; (ii)  $\text{LiAlH}_4$ ,  $\text{Et}_2\text{O}$ , room temperature, 4 h, 98%; (iii)  $t\text{-BuMe}_2\text{SiCl}$ , imidazole, DMF, room temperature, 18 h, 93%; (iv)  $(i\text{-Bu})_2\text{AlH}$ ,  $\text{Et}_2\text{O}$ , room temperature, 4 h, 70%; (v)  $\text{ClCH}_2\text{OCH}_3$ ,  $(i\text{-Pr})_2\text{NEt}$ ,  $\text{CH}_2\text{Cl}_2$ , room temperature, 4 h, 79%; (vi)  $\text{Bu}_4\text{NF}$ , THF, room temperature, 2 h, 73%; (vii)  $(\text{COCl})_2$ , DMSO,  $\text{CH}_2\text{Cl}_2$ ,  $-78^\circ\text{C}$ , 1 h, then  $\text{Et}_3\text{N}$ , 1 h, 60%; (viii)  $\text{Ph}_3\text{PCH}_2$ , THF,  $0^\circ\text{C}$ , 1 h, then room temperature, 1 h, 70%; (ix) concentrated HCl catalyst, MeOH,  $\Delta$ , 1 h, 99%; (x)  $p\text{-TsCl}$ , py,  $0^\circ\text{C}$ , 24 h, then room temperature, 24 h, 74%; (xi) NaI,  $\text{CH}_3\text{COCH}_3$ ,  $\Delta$ , 18 h, then in 2-butanone,  $\Delta$ , 48 h, 63%.

Scheme V<sup>a</sup>

<sup>a</sup> (i) Mg, THF,  $\Delta$ , 6 h; (ii) CuI, THF, then 34, room temperature, 5 days, 33-42%.

26 under Swern conditions afforded aldehyde 30 which was transformed to 31 in a Wittig reaction. This diene was unmasked to yield 32, and the latter was converted to diiodide 34 via its bis tosylate 33.

The union of 2 equiv of 10 with 34 was investigated under a variety of conditions, and, although coupling could be effected rapidly at the sterically less encumbered terminus of 34, the neopentyl iodide proved to be extremely sluggish in its reactivity. Eventually, it was found that preparation of Grignard reagent 35, followed by treatment with anhydrous cuprous iodide, afforded an alkylcopper species<sup>13</sup> that underwent slow reaction with 34 to give botryococcene (1) (see Scheme V). The synthetic material was identical with the natural hydrocarbon in all respects, including optical rotation. This first synthesis of a member of the botryococcene family, together with the stereochemical investigation completed earlier,<sup>5</sup> sets the stage for biogenetic and other studies of this intriguing class of terpenoids.

**Acknowledgment.** We are indebted to Professor Arthur G. Schultz for providing unpublished information and to Professor Douglas A. Keszler for assistance with the X-ray crystal structure determination. Financial support for this research was provided by the National Science Foundation (CHE-8619029) and by the Petroleum Research Fund, administered by the American

Chemical Society, through a Summer Research Fellowship to G.O.S. Funds for the purchase of a Bruker AM 400 NMR spectrometer and a Rigaku X-ray diffractometer were provided by the National Science Foundation.

**Supplementary Material Available:** Spectral data are available for compounds 1, 3-7, 9, 10, 12-15, 18, 19, 21, 22, 24-31, and 33 (8 pages). Ordering information is given on any current masthead page.


A Model for the Proposed Mechanism of Action of the Potent Antitumor Antibiotic Esperamicin A<sub>1</sub>

Philip Magnus\* and Paul A. Carter

Department of Chemistry, Indiana University  
Bloomington, Indiana 47405

Received November 19, 1987

Very recently two groups reported the extraordinary structures of a new class of extremely potent antitumor antibiotics, of which esperamicin A<sub>1</sub> 1 has the common aglycone bicyclo[7.3.1]diynene system.<sup>1</sup> Co-occurring with these metabolites is an inactive



compound, esperamicin X 2.<sup>2</sup> It was speculated that the mode of biological action of 1 involves nucleophilic attack on the central sulfur atom and thiol addition to the  $\alpha,\beta$ -unsaturated carbonyl group to give the putative intermediate 3 (see Scheme I). It was suggested that the change of hybridization at C-1 from  $\text{sp}^2$  to  $\text{sp}^3$ , in effect, pulls together the ends of the diyne C-6 and C-11 to allow cyclization of the diyne 3 into the 1,4-diyl(*p*-benzynes) 4. This diradical can abstract a hydrogen atom from the sugar phosphate backbone of DNA and result in strand scission. While 3 can cyclize to the [3.3.1]system 4, esperamicin 1 cannot, since the transition state would be prohibitively high due to the bridgehead double bond at C-1. Consequently, the triggering thiol addition at C-1 does more than reduce the distance between C-6 and C-11, it allows access to a reasonable kinetic pathway to 4. The 1,4-diyl process has a parallel in the earlier work of Bergman,<sup>3</sup> who showed that the prototype diyne 5 could be converted into benzene and 1,4-dichlorobenzene when exposed to 1,4-cyclohexadiene and  $\text{CCl}_4$ , respectively. The conditions ( $195^\circ\text{C}$ ) hardly parallel the mild conditions (room temperature to  $37^\circ\text{C}$ ) speculated for the conversion of 3 into 4. The  $\Delta G^\ddagger$  for the conversion of 5 into benzene via the 1,4-diyl is approximately  $32 \text{ kcal mol}^{-1}$ .


(1) Golik, J.; Dubay, G.; Groenewold, G.; Kawaguchi, H.; Konishi, M.; Krishnan, B.; Ohkuma, H.; Saitoh, K.-i.; Doyle, T. W. *J. Am. Chem. Soc.* **1987**, *109*, 3462. Lee, M. D.; Dunne, T. S.; Siegel, M. M.; Chang, C. C.; Morton, G. O.; Borders, D. B. *J. Am. Chem. Soc.* **1987**, *109*, 3464. This latter reference describes the calicheimicins: Lee, M. D.; Dunne, T. S.; Chang, C. C.; Ellestad, G. A.; Siegel, M. M.; Morton, G. O.; McGahren, W. J.; Borders, D. B. *J. Am. Chem. Soc.* **1987**, *109*, 3466.

(2) Golik, J.; Clardy, J.; Dubay, G.; Groenewold, G.; Kawaguchi, H.; Konishi, M.; Krishnan, B.; Ohkuma, H.; Saitoh, K.-i.; Doyle, T. W. *J. Am. Chem. Soc.* **1987**, *109*, 3461.


(3) Bergman, R. G. *Acc. Chem. Res.* **1973**, *6*, 25. Lockhart, T. P.; Comita, P. B.; Gergman, R. G. *J. Am. Chem. Soc.* **1981**, *103*, 4082. Lockhart, T. P.; Bergman, R. G. *J. Am. Chem. Soc.* **1981**, *103*, 4091. Jones, R. R.; Bergman, R. G. *J. Am. Chem. Soc.* **1972**, *94*, 660. The conversion of diynes into antisymmetric benzene-1,4-diyl is a symmetry-allowed process: Hoffman, R.; Imamura, A.; Hehre, W. J. *J. Am. Chem. Soc.* **1968**, *90*, 1499. Dewar, M. J. D.; Li, W.-K. *J. Am. Chem. Soc.* **1974**, *96*, 5569. For biradical reactivity, see: Chapman, O. L.; Chang, C. C.; Koie, J. *J. Am. Chem. Soc.* **1976**, *98*, 5703. Darby, N.; Kim, C. U.; Salaun, J. A.; Shelton, K. W.; Takeda, S.; Masamune, S. *J. Chem. Soc. D.* **1971**, 1516. Wong, H. N. C.; Sondheimer, F. *Tetrahedron Lett.* **1980**, *21*, 217.

(13) Tamura, M.; Kochi, J. *J. Am. Chem. Soc.* **1971**, *93*, 1485.

Scheme I




Scheme II



Benzene-1,4-diyl is only 14 kcal mol<sup>-1</sup> in energy above the diyne **5**. Consequently, the strain energy in **3** must be sufficient to overcome the potential activation energy of 32 kcal mol<sup>-1</sup> at ambient temperatures. This requires that the release of strain energy going from **3** to **2** should be at least 10–12 kcal mol<sup>-1</sup> in order to proceed at a reasonable rate at room temperature. With this in mind, we have constructed a model system that maintains C-1 as sp<sup>3</sup> hybridized yet prevents cyclization into the diyne, because one of the triple bonds is complexed as its derived dicobalt hexacarbonyl metalocycle.<sup>4</sup> This device allows us to examine the release of the diyne by oxidation and the cyclization to a 1,4-diyl in the absence of the initiating thiol chemistry. In the course of their studies on calichecins,<sup>1</sup> the Lederle group has converted the analogue of **1** into the calichecin analogue of **2** and observed deuterium incorporation into the para positions of the aromatic ring when this transformation was carried out in the presence of CD<sub>2</sub>Cl<sub>2</sub>.

Treatment of cyclohexane-1,4-dione monoketal with lithium acetylide gave **6** (66%), which was coupled with (*Z*)-dichloroethylene with use of Pd(PPh<sub>3</sub>)<sub>4</sub>/CuI/*n*-BuNH<sub>2</sub>/PhH to give **7** (65%) (see Scheme II). Protection (*t*-BuMe<sub>2</sub>SiOTf/NEt<sub>3</sub>/CH<sub>2</sub>Cl<sub>2</sub>) of **7** as its *tert*-butyldimethylsilyl ether **8** (82%) and mild acid hydrolysis of **8** gave **9** (88%). Coupling (Pd(PPh<sub>3</sub>)<sub>4</sub>/CuI/*n*-BuNH<sub>2</sub>/PhH) with propargyl methyl ether gave **10** (74%).<sup>5</sup> As expected, when **10** was treated with Co<sub>2</sub>(CO)<sub>8</sub> (1.0 equiv) in heptane the least hindered acetylene was converted into the di-

Scheme III



cobalt hexacarbonyl cluster **11** (82%). The structure of **11** was unambiguously confirmed by a single-crystal X-ray structure of the alcohol **12**.<sup>6</sup> This shows that in the solid state the linear acetylene portion occupies an equatorial conformation. The compound **11** can only cyclize via the propargyl cation in the axial conformation **11a**. Treatment of **11** with *t*-BuMe<sub>2</sub>SiOTf/NEt<sub>3</sub>/CH<sub>2</sub>Cl<sub>2</sub> gave **13** (89%). When **13** was exposed to TiCl<sub>4</sub> (6 equiv)/DABCO (1 equiv) at -78 °C, followed by warming to -50 °C, the cyclized product **14** (45%) was obtained as a stable compound<sup>7</sup> (see Scheme III). The <sup>1</sup>H NMR showed that the methyl groups attached to Si are no longer equivalent due to hindered rotation. Oxidative decomplexation of **14** in 1,4-cyclohexadiene using *N*-methylmorpholine *N*-oxide<sup>8</sup> at 20 °C rapidly gave **17** (50%). Similarly, conducting the same decomplexation in CCl<sub>4</sub>/*t*-BuOH gave **18** (29%).<sup>9</sup> We could not detect the intermediate diyne **15**. It is important to note that the acyclic enediyne dicobalt hexacarbonyl adduct **11** can be oxidatively decomplexed to give the enediyne **10** without aromatization. Therefore, we believe that the conversion of **14** via **15** into **16** is not complicated by a cobalt-catalyzed process and proceeds via the decomplexed enediyne **15**. Molecular models of **14** show that the Co<sub>2</sub>(CO)<sub>6</sub> cluster locks **14** in the conformation shown, which also corresponds to the one needed (**13a**) to arrive at **14**. This is because the usual linear acetylene is bent in the Co<sub>2</sub>(CO)<sub>6</sub> cluster from 180° to approximately 145°. When the Co<sub>2</sub>(CO)<sub>6</sub> residue is oxidatively removed it should directly generate **15**, which is the higher energy conformer needed to produce the diyne **16**. The linearynes in **15** are more strained than in **15a** where the cyclohexyl ring is in a boat conformation. MMX calculations, which are parameterized to allow for the weak sp bending modes, suggest that **15** is approximately 3 kcal mol<sup>-1</sup> more strained than **15a**. Comparing the differences in potential energies between **15a** and **17** (the *t*-OR substituent is removed) and between **5** and benzene or the 1,6-dimethyl analogue of **5**, into *o*-xylene, it was found that overall there is an 8.8 kcal mol<sup>-1</sup> lowering of Δ*H*<sup>‡</sup> for the conversion of **15a** into **17** relative to the references.<sup>10</sup> This means

(6) The complete details of the single-crystal X-ray structural determination of **12** may be obtained from Dr. John Huffman, Molecular Structure Center, Indiana University, IN 47405. Please ask for structure report no. 87190.

(7) The propargyl cation chemistry has recently been reviewed: Nicholas, K. M. *Acc. Chem. Res.* **1987**, *20*, 207. Nicholas, K. M.; Mulraney, M.; Bayer, M. *J. Am. Chem. Soc.* **1980**, *102*, 2508. Schreiber, S. L.; Sammakia, T.; Crowe, W. E. *J. Am. Chem. Soc.* **1986**, *108*, 3128. Schreiber, S. L.; Klimas, M. Y.; Sammakia, T. *J. Am. Chem. Soc.* **1987**, *109*, 5749.

(8) Magnus, P.; Becker, D. P. *J. Chem. Soc., Chem. Commun.* **1985**, 640.

(9) Compound **17** (X = H; R = H) is known: Hook, J. M.; Mander, L. N. *J. Org. Chem.* **1980**, *45*, 1722.

(10) Here the aromatic material is used as a model for the transition state leading to the diyne. The MMX calculations used the VESCF π routines from MM1 (QCPE no. 318) to adjust unsaturated carbon distances. The rest of the force field in MMX is similar to that in MM2, except for sp carbon bending force constants being one third the MM2 values. The stiffer sp bending constants in MM2 give a 3.5 kcal/mol higher strain energy in **15a**. The potential energy of (*Z*)-bis(1'-propynyl)ethene is -3.47 kcal/mol and *o*-xylene is 9.77 kcal/mol; the value for **15a** is 16.27 kcal/mol and that for **17** is 20.7 kcal/mol. MMX is available from Serena Software.

(4) Sly, W. G. *J. Am. Chem. Soc.* **1959**, *81*, 18. Gregson, D.; Howard, J. A. K. *Acta Crystallogr., Sect. C: Cryst. Struct. Commun.* **1983**, *C39*, 1024.

(5) Coupling procedures follow literature methods, see: Ratovelomanana, V.; Linstrumelle, G. *Tetrahedron Lett.* **1984**, *25*, 6001. Guillerme, D.; Linstrumelle, G. *Tetrahedron Lett.* **1986**, *27*, 5857. These authors report the synthesis of the diyne **1**, which is a stable lactone: Guillerme, D.; Linstrumelle, G. *Tetrahedron Lett.* **1985**, *26*, 3811. Ratovelomanana, V.; Linstrumelle, G. *Tetrahedron Lett.* **1981**, *22*, 207. Stephans, R. D.; Castro, C. E. *J. Org. Chem.* **1963**, *28*, 3313.



that  $E_{\text{act}}$  for the conversion of **15a** into **17** is approximately 18.6 kcal mol<sup>-1</sup> ( $t_{1/2}$  334 s at 300 K). Thus we have demonstrated that the diyne **15** is sufficiently strained that even at room temperature it undergoes rapid cyclization into the 1,4-diyl **16**. The products **17** and **18** are clear indications of a radical abstraction process and provide substantial vindication of the proposed mechanism. We are currently pursuing more elaborate models that contain the C-12 oxygen substituent and the C-13,14-double bond.<sup>11</sup>

**Acknowledgment.** The National Institutes of Health are gratefully thanked for their support. Dr. Terry Doyle (Bristol-Myers) is thanked for helpful discussions. Dr. John Huffman, Molecular Structure Center, Indiana University, Bloomington, IN 47405, is thanked for the X-ray structural determinations. Dr. J. Gajewski is thanked for carrying out the MMX calculations and discussions on the above problems.

(11) NMR data for **10**, **11**, **14**, and **17** are as follows. **10**: <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 5.86 (2 H, m), 4.21 (2 H, d,  $J$  = 1.8 Hz), 3.36 (3 H, s), 2.50 (4 H, m), 2.14 (4 H, t,  $J$  = 6.9 Hz), 0.87 (9 H, s), 0.21 (6 H, s); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 209.68 (s), 119.57 (d), 118.81 (d), 98.75 (s), 92.90 (s), 83.40 (s), 83.01 (s), 67.75 (s), 60.21 (t), 57.61 (q), 40.14 (t), 37.40 (t), 25.80 (q), 18.13 (s), -3.00 (q). **11**: <sup>1</sup>H NMR (300 MHz, C<sub>6</sub>D<sub>6</sub>) δ 6.32 (1 H, d,  $J$  = 11.0 Hz), 5.50 (1 H, d,  $J$  = 11.0 Hz), 4.59 (2 H, s), 3.19 (3 H, s), 2.55 (2 H, m), 2.23 (2 H, m), 1.8-2.1 (2 H, m), 0.95 (9 H, s), 0.22 (6 H, s); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 209.77 (s), 198 (m), 136.82 (d), 109.84 (d), 102.22 (s), 94.18 (s), 83.39 (s), 81.76 (s), 73.38 (t), 67.44 (s), 58.99 (q), 39.74 (t), 37.18 (t), 25.85 (q), 18.40 (s), -2.84 (q). **14**: <sup>1</sup>H NMR (300 MHz, C<sub>6</sub>D<sub>6</sub>) δ 6.88 (1 H, d,  $J$  = 9.4 Hz), 5.64 (1 H, d,  $J$  = 9.4 Hz), 3.20 (3 H, m), 2.7 (2 H, m), 2.3 (4 H, m), 0.92 (9 H, s), 0.26 (3 H, s), 0.18 (3 H, s); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 209.52 (s), 198.74-199.13 (m), 142.69 (d), 109.50 (d), 102.70 (s), 99.28 (s), 88.63 (s), 83.11 (s), 69.78 (s), 56.64 (d), 45.42 (t), 41.09 (t), 36.81 (t), 35.36 (t), 25.84 (q), 18.28 (s), -3.10 (q). **17**: <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.35-7.19 (4 H, m), 3.37 (1 H, dd,  $J$ 's = 9.0 and 17.4 Hz), 2.82 (1 H, m), 2.67 (1 H, dd,  $J$ 's = 6.2 and 15.7 Hz), 2.59 (1 H, m), 2.52 (1 H, dd,  $J$ 's = 5.2 and 17.4 Hz), 2.31 (2 H, m), 2.16 (2 H, m), 0.87 (9 H, s), -0.06 (3 H, s), -0.19 (3 H, s).

## Does Dehydroquinase Synthase Synthesize Dehydroquinase?


Paul A. Bartlett\* and Kunio Satake

Department of Chemistry, University of California  
Berkeley, California 94720

Received November 2, 1987


The biosynthetic conversion of 3-deoxy-D-arabino-heptulosonic acid 7-phosphate (DAHP) to 3-dehydroquinic acid (DHQ), attributed to 3-dehydroquinase synthase (EC 4.6.1.3), occurs at an early stage of the shikimate pathway.<sup>1</sup> The mechanistic details of the transformation (Scheme I)<sup>2</sup> reflect both clever functional group manipulation and stereochemical dexterity on the part of the enzyme. Temporary introduction of a ketone at C-5 of DAHP facilitates elimination of phosphate and generation of an enolpyranose **3**. From this intermediate, ring opening and rotation of the ensuing acyclic enol or enolate ( $\rightarrow$  **4**) set the stage for ring closure via an aldol condensation to provide the observed product, DHQ. We report here the nonenzymatic generation of enolpyranose **3** and observations of its chemical behavior which suggest that its biosynthetic conversion to DHQ may not be an enzyme-catalyzed process.

The enolpyranose **3** was expected to be unstable both toward isolation as well as under acidic or basic conditions typically



**Figure 1.** (a) There is 5.6 mg of **15** in 0.65 mL of 0.1 M phosphate buffer (0.39 mmol of NaH<sub>2</sub>PO<sub>4</sub> and 0.61 mmol of Na<sub>2</sub>HPO<sub>4</sub> in 10.0 mL of D<sub>2</sub>O): m = methanol. (b) Solution from (a) after irradiation for 15 min at 0 °C: m = methanol, s = residual **15**. (c) Authentic DHQ in phosphate buffer. (d) Solution from irradiation of (7Z)-(7-<sup>2</sup>H)-**15** (94% stereoisomeric purity) under the same conditions as (a): m = methanol.

## Scheme I



utilized for removal of hydroxyl- or ketal-protecting groups. *o*-Nitrobenzyl ketal **15** was therefore chosen as the immediate precursor to **3**, since deprotection could be accomplished photochemically under neutral conditions.<sup>3</sup> This intermediate was synthesized from methyl 3-deoxy-D-arabino-heptulosonate, **5**,<sup>4</sup> as shown in Scheme II.<sup>5</sup>

(1) Weiss, U.; Edwards, J. M. *The Biosynthesis of Aromatic Compounds*; Wiley: New York, 1980. Ganem, B. *Tetrahedron* **1978**, *34*, 3353. Haslam, E. *The Shikimate Pathway*; Wiley: New York, 1974.

(2) (a) Rotenberg, S. L.; Sprinson, D. B. *J. Biol. Chem.* **1978**, *253*, 2210-15. Maitra, U. S.; Sprinson, D. B. *J. Biol. Chem.* **1978**, *253*, 5426-30. (b) Turner, M. J.; Smith, B. W.; Haslam, E. *J. Chem. Soc., Perkin Trans. I* **1975**, 52-55. (c) Le Maréchal, P.; Azerad, R. *Biochimie* **1976**, *58*, 1123-28. (d) Lambert, J. M.; Boocock, M. R.; Coggins, J. R. *Biochem. J.* **1985**, *226*, 817. (e) Widlanski, T. S.; Bender, S. L.; Knowles, J. R. *J. Am. Chem. Soc.* **1987**, *109*, 1873-1875.

(3) Zehavi, E.; Amit, B.; Patchornik, A. *J. Org. Chem.* **1972**, *37*, 2281. Zehavi, E.; Patchornik, A. *J. Org. Chem.* **1972**, *37*, 2285.

(4) Compound **5** was prepared by Dowex 50W X8-catalyzed hydrolysis of the corresponding diacetone as described in the following: Frost, J. W.; Knowles, J. R. *Biochemistry* **1984**, *23*, 4465-4469.